Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.
Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.
复制标题
DOI：
10.3390/ph15020200
复制
发表时间：
2022-02-05
期刊：
影响因子：
--
通讯作者：
Wiśniewska M
中科院分区：
文献类型：
--
作者：
Kotfis K;Karolak I;Lechowicz K;Zegan-Barańska M;Pikulska A;Niedźwiedzka-Rystwej P;Kawa M;Sieńko J;Szylińska A;Wiśniewska M
2019年12月，SARS-CoV-2病毒在全球出现，主要表现为下呼吸道急性感染，即肺炎。近10%的患者在感染后表现出明显的肺纤维化变化。本研究旨在评价坎利酸钾治疗COVID-19相关肺炎和肺纤维化的有效性和安全性。我们进行了坎利酸钾与安慰剂的随机临床试验（RCT）。共有55例患者接受随机化，49例纳入最终分析（24例分配至干预组，25例分配至对照组）。通过体格检查、肺部超声、CT成像和血液样本进行生化分析对患者进行评估。这项随机对照试验表明，对COVID-19诱导的肺炎患者给予坎利酸钾与机械通气时间更短、被动氧合时间更短、住院时间更短或CT成像纤维化变化更少无关。两组的总体死亡率无显著差异。本研究中记录的不良事件并未因坎利酸钾给药而显著增加。研究的负面结果可能与纳入的患者数量相对较少有关。在COVID-19患者中使用坎利酸钾作为抗纤维化药物的任何可能的益处都需要进一步研究。
In December 2019 the SARS-CoV-2 virus appeared in the world, mainly presenting as an acute infection of the lower respiratory tract, namely pneumonia. Nearly 10% of all patients show significant pulmonary fibrotic changes after the infection. The aim of this study was to evaluate the effectiveness and safety of potassium canrenoate in the treatment of COVID-19-associated pneumonia and pulmonary fibrosis. We performed a randomized clinical trial (RCT) of potassium canrenoate vs placebo. A total of 55 patients were randomized and 49 were included in the final analysis (24 allocated to the intervention group and 25 allocated to the control group). Patients were assessed by physical examination, lung ultrasound, CT imaging and blood samples that underwent biochemical analysis. This RCT has shown that the administration of potassium canrenoate to patients with COVID-19 induced pneumonia was not associated with shorter mechanical ventilation time, shorter passive oxygenation, shorter length of hospitalization or less fibrotic changes on CT imaging. The overall mortality rate was not significantly different between the two groups. Adverse events recorded in this study were not significantly increased by the administration of potassium canrenoate. The negative outcome of the study may be associated with the relatively small number of patients included. Any possible benefits from the use of potassium canrenoate as an antifibrotic drug in COVID-19 patients require further investigation.
登录
查看更多内容
螺内酯部分通过调节循环和肺泡室中的单核吞噬细胞表型转换来减轻博来霉素引起的肺损伤
影响因子：
3.7
作者：
Ji WJ;Ma YQ;Zhou X;Zhang YD;Lu RY;Guo ZZ;Sun HY;Hu DC;Yang GH;Li YM;Wei LQ
通讯作者：
Wei LQ
DOI：
10.3390/ph14010071
发表时间：
2021-01-17
期刊：
Pharmaceuticals (Basel, Switzerland)
影响因子：
--
作者：
Kotfis K;Lechowicz K;Drożdżal S;Niedźwiedzka-Rystwej P;Wojdacz TK;Grywalska E;Biernawska J;Wiśniewska M;Parczewski M
通讯作者：
Parczewski M
影响因子：
5
作者：
Lieber, Gissela B.;Fernandez, Xiomara;McLeod, Robbie L.
通讯作者：
McLeod, Robbie L.
影响因子：
--
作者：
Adams, Constantin;Icheva, Vanya;Riethmueller, Joachim
通讯作者：
Riethmueller, Joachim
严重急性呼吸综合症对幸存者队列中肺功能，运动能力和生活质量的1年影响。
影响因子：
9.6
作者：
Hui DS;Wong KT;Ko FW;Tam LS;Chan DP;Woo J;Sung JJ
通讯作者：
Sung JJ